Denali Therapeutics Inc. (DNLI)
| Previous close | 16.16 |
| Open | 16.41 |
| Bid | 16.31 x 100 |
| Ask | 16.41 x 100 |
| Day's range | 15.92 - 16.47 |
| 52-week range | 14.56 - 33.31 |
| Volume | |
| Avg. volume | 1,258,211 |
| Market cap | 2.331B |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.06 |
| Earnings date | 06 May 2024 - 10 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41.19 |
GlobeNewswireDenali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative and lysosomal storage diseases, today announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial, which
Simply Wall St.Is There An Opportunity With Denali Therapeutics Inc.'s (NASDAQ:DNLI) 50% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Denali Therapeutics fair value estimate is US$30.74 Denali...
ZacksWhy Denali Therapeutics (DNLI) Stock Might be a Great Pick
Denali Therapeutics (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
